Continued Ventilation During Cardiopulmonary Bypass

Continued Mechanical Ventilation During CABG Operation Attenuates Systemic Immune Modulation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01627756

Enrollment

Registered

2012-06-26

Start date

2009-04-30

Completion date

2010-08-31

Last updated

2020-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Thoracic Surgery, Endotoxins, Respiration, Artificial, Immune System

Brief summary

Cardiopulmonary bypass (CPB) is well known to induce a strong anti-inflammatory response. The investigators examined whether continued mechanical ventilation during CPB alters systemic immune activation.

Detailed description

Cardiopulmonary bypass is well known to induce a strong anti-inflammatory response. Studies had been shown that the contact of blood components with artificial surfaces, the surgical trauma, endotoxemia and a reperfusion injury are in part responsible for the seen immunological affect after surgery. The purpose of this study is to test the effect of continued mechanical ventilation during surgery on a blood marker called soluble ST2 in patients sera. Soluble ST2 acts as a decoy receptor of IL-33 and has anti-inflammatory effects. Elevated soluble ST2 concentrations are reported in patients with acute myocardial infarction, sepsis, congestive heart failure and elevates soluble ST2 levels are associated with adverse outcome.

Interventions

OTHERLung Ventilation

In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.

OTHERNon-ventilated Group

. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Written informed consent * age \> 40 and \< 80

Exclusion criteria

* treatment with steroids or immunomodulatory interventions during the past four weeks * signs of an acute infection

Design outcomes

Primary

Measure	Time frame	Description
Alteration of soluble ST2 concentration in serum	Preoperative, postoperative, day 1, day 2, day 3, day 4, day 5 after surgery	Concentration of soluble ST2 will be assessed in the serum of patient´s preoperativem, postoperative and the following five consecutive days after surgery.

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026